Genomic Testing in the NCI-MATCH Cancer Trial

To find patients who may be eligible, several commercial and academic laboratories were permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial. These referrals were based upon each lab’s standard tumor gene tests ordered by physicians at participating trial sites to guide clinical care for their patients.

The laboratory referral process applied to any cancer patient who had tumor gene testing through a cancer center or community hospital that participated in the trial. NCI-MATCH was open at nearly 1100 clinical sites in every state, the District of Columbia, and Puerto Rico.

The trial closed to patient enrollment on December 23, 2022.

Designated Commercial Laboratories

Ashion Analytics
Caris Life Sciences
CellNetix Pathology and Laboratories
Foundation Medicine
GenPath (BioReference Laboratories)
NeoGenomics Laboratories
PathGroup
Quest Diagnostics
Strata Oncology
Tempus Labs
The Jackson Laboratory

Designated Academic Laboratories

Augusta University
Brigham and Women’s Hospital
Cedars-Sinai Medical Center
City of Hope National Medical Center
Columbia University
Frederick National Laboratory for Cancer Research
Johns Hopkins Genomics
Mass General Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute – Laboratory of Pathology
Stanford Health Care
The University of Texas MD Anderson Cancer Center
University of Chicago
University of Colorado
University of Michigan
University of Washington
Weill Cornell Medicine
Yale University

NCI-MATCH

Trial Locations

Notes:

This study entry process intended for participating NCI-MATCH trial sites to order testing from the designated commercial labs

Patients and physicians were able to send emails directly to the designated commercial labs to request a review of a genomic test or seek general information--there was no need to contact the NCI or ECOG-ACRIN

Generally, the designated academic labs, which are located in cancer centers and at the NCI, identified potential trial candidates from their own patient populations